Article information
Full text is only aviable in PDF
Bibliografía
[1.]
R. Rosell Costa.
Quimioterapia en enfermos con carcinoma de pulmón no de células pequeñas. Estadios localmente avanzados diseminados.
Avances en Oncología, Arán S.A, (1988), pp. 137-142
[2.]
V.T. De Vita, S. Hellman, S.A. Rosenberg.
Cáncer. Principios y práctica de Oncología.
Ed. Salvat, (1984), pp. 371
[3.]
L.A. Loeb, V.L. Ernster, K.E. Warner, J. Abbotts, J. Laszlo.
Smoking and lung cancer: an overview.
Cancer Res, 44 (1984), pp. 5.940-5.958
[4.]
N. Martini, M.S. Bains, P. McCormack.
Surgical treatment in nonsmall cell carcinoma of the lung: The Memorial Sloan-Kettering experience.
Lung tumors, Ed Springer-Verlag, (1988), pp. 111132
[5.]
A. Ordóñez, C. Garcia Girón, J. Feliu.
Estado actual en el tratamiento del carcinoma broncopulmonar de células pequeñas.
Arch Bronconeumol, 24 (1988), pp. 15-20
[6.]
M.J. Strauss.
Lung cancer.
Ed Grune-Stratton, (1983), pp. 21-35
[7.]
P. Santabárbara, J. Estapé.
Historia natural del cáncer de pulmón.
Rev Cáncer, 1 (1987), pp. 161-169
[8.]
D.A. Casciato, B.B. Lowitz.
Manual of Bedside Oncology.
Little, Brown and Co, (1983), pp. 153
[9.]
M. Gallén, J.L. Minguella, J. Plana, J. Broquetas, J.M. Sastre, N. Malats.
Supervivencia en la cirugía del cáncer de pulmón Análisis de factores pronósticos.
Arch Bronconeumol, 24 (1988), pp. 161-164
[10.]
A.J. Torres, A. Suárez, J.L. Balibrea.
Tratamiento quirúrgico del cáncer de pulmón no oat cell.
Rev Cancer, 1 (1987), pp. 145-152
[11.]
C.F. Mountain.
A new international staging of lung cancer.
Arch Bronconeumol, 23 (1987), pp. 298-305
[12.]
C. León.
Nueva clasificación por estadios en el carcinoma broncogénico.
Arch Bronconeumol, 23 (1987), pp. 273-274
[13.]
F.G. Pearson.
Lung cancer The past twenty-five years.
Chest, 89 (1986), pp. 200-205
[14.]
M. Merlier, H. Le Brigand.
Supervivencia a largo plazo de los cánceres bronquiales primitivos operados.
Press Médic (Ed. esp), 6 (1984), pp. 285-288
[15.]
P. Darteville, J. Marzelle.
Extended operations for T3-T4 primary lung cancer. Indications and results.
Lung Cancer, 4 (1988), pp. 41-42
[16.]
C.F. Mountain.
Cáncer de pulmón Topics in cancer.
JANO, 661 (1985), pp. 716-724
[17.]
R.J. Ginsberg.
Limited resection in the treatment of stage I non-small cell lung cancer An overview.
Lung Cancer, 4 (1988), pp. 40
[18.]
M.R. Johnston.
Selecting patients with lung cancer for surgical therapy.
Sem Oncol, 15 (1988), pp. 246-254
[19.]
R. Souhami, J. Tobias.
Cancer and its management.
Blackwell Scientific Publ, (1987), pp. 202
[20.]
M.H. Gail, R.T. Eagan, R. Feld, et al.
Prognostic factors in patients with resected stage I non-small cell lung cancer. A report from the lung Cancer Study Group.
Cancer, 54 (1984), pp. 1.802-1.813
[21.]
H.H. Hansen, F.R. Hirsch, M. Rorth.
Treatment at the Finsen Institute.
Lung Tumors, Ed. Springer-Verlag, (1988), pp. 97-109
[22.]
D.L. Paulson.
The survival rate in superior sulcus tumors treated by presurgical irradiation.
JAMA, 196 (1986), pp. 342
[23.]
T.M. Anderson, P.M. Moy, E.C. Holmes.
Factors affecting survival in superior sulcus tumors.
J Clin Oncol, 4 (1986), pp. 1.598-1.603
[24.]
R. Sealy, S. Lagakos, T. Barkley, et al.
Radiotherapy of regional epidermoid carcinoma of the lung. A study in fractionation.
Cancer, 49 (1982), pp. 1.338-1.345
[25.]
R. Arriagada, T. Le Chevalier.
Report on the IASLC Le Havre Workshop on combined modality treatment in non-small cell lung cancer.
Lung Cancer, 4 (1988), pp. 59
[26.]
J. Aisner, H.H. Hansen.
Commentary: current status of chemotherapy for non-small cell lung cancer.
Cancer Treat Rep, 65 (1981), pp. 979-986
[27.]
R.L. Woods, J.A. Levi, J. Page, et al.
Non small cell cancer: a randomized comparison of chemotherapy with non chemotherapy.
Proc 21 th Meeting ASCO, 4 (1985), pp. 167
[28.]
Y. Cormier, D. Bergeron, J. La Forge, et al.
Benefits of polychemotherapy in advanced non small cell bronchogenic carcinoma.
Cancer, 50 (1982), pp. 845-849
[29.]
J.A. Knost, F.A. Greco, K.R. Hande, R.L. Richardson, M.F. Fer, R.K. Oldham.
Cyclophosphamide, doxorrubicin and cisplatin in the treatment of advanced non-small cell lung cancer.
Cancer Treat Rep, 65 (1981), pp. 941-945
[30.]
J.A. Elliot, S. Ahmedzai, D. Hole, et al.
Vindesine and cisplatin combinations chemotherapy compared with vindesine as a single agent in the management of non-small cell lung cancer. A randomized study.
Eur J Cancer Clin Oncol, 20 (1984), pp. 1.025-1.032
[31.]
M.I. Loretta, R.J. Gralla, D.P. Kelsen, et al.
Cisplatin, vindesine and bleomycin (CVB) Combination chemotherapy of advanced non-small cell lung cancer.
Cancer, 51 (1983), pp. 1.050-1.055
[32.]
J. Bitran, R.K. Desser, T.R. DeMeester, et al.
Cyclophosphamide, adriamycin, methotrexate and procarbazine (CAMP), effective fourdrug combination chemotherapy for metastasic non-oat cell bronchogenic carcinoma.
Cancer Treat Resp, 60 (1976), pp. 1.225-1.230
[33.]
H.H. Hansen, M. Rorth.
Lung cancer.
Cancer chemotherapy and biological response modifiers. Annual 10’, pp. 222-240
[34.]
G. Anderson, H. Payne.
Response rate and toxicity of etoposide (VP-16) in squamous carcinoma of the lung Report from the lung cancer Treatment Study Group.
SemOncol, 12 (1985), pp. 21-22
[35.]
L.H. Einhorn, P.J. Loehrer, S.D. Williams, et al.
Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small cell lung cancer.
J Clin Oncol, 4 (1986),
[36.]
A.P. Chahinian, D.L. Arnold, J.M. Cohen, et al.
Chemotherapy for bronchogenic carcinoma, Methotrexate, doxorrubicin, cyclophosphamide and lomustine.
JAMA, 237 (1977), pp. 2.392-2.396
[37.]
S.E. Vogl, C.R. Mehta, M.H. Cohen.
MACC chemotherapy for adenocarcinoma and epidermoid carcinoma of the lung Low response rate in a cooperative group study.
Cancer, 44 (1979), pp. 864-868
[38.]
J. Klastersky, J.P. Sculier, C. Nicaise, et al.
Combination chemotherapy with cisplatin, etoposide and vindesine in non small cell lung carcinoma: A clinical trial of the EORTC Lung Cancer Working Party.
Cancer Treat Rep, 67 (1983), pp. 727-730
[39.]
T.E. Lad, R.B. Nelson, U. Diekamp, et al.
Immediate versus postponed combination chemotherapy (CAMP) for unresectable non-small cell lung cancer. A randozimed trial.
Cancer Treat Rep, 65 (1981), pp. 973-978
[40.]
J.P. Sculier, J. Klastersky.
Progress in chemotherapy on non-small cell lung cancer.
Eur J Cancer Clin Oncol, 20 (1984), pp. 1.329-1.333
[41.]
W.K. Evans, R. Feld, G. De Boer.
Cyclophosphamide, doxorrubicin and cisplatin in the treatment of non-small cell bronchogenic carcinoma.
Cancer Treat Rep, 65 (1981), pp. 947-954
[42.]
Klastersky J. Tratamiento del cáncer de pulmón avanzado no de células pequeñas. Rev Cancer; 1:170-178.
[43.]
J. Klastersky, J.P. Sculier, G. Bureau.
Cisplatin versus cisplatin plus etoposide. A randomized study in advanced non-small cell lung cancer.
Proc ASCO, 201 (1988), pp. 775
[44.]
R.J. Fraila, E.S. Caspers, D.P. Kelsen.
Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung. A randomized trial investigating two dosage schedules.
Ann Inter Med, 95 (1981), pp. 414-420
[45.]
E. Longeval, J. Klastersky.
Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma. A study by the EORTC Lung Cancer Working Party (Belgium).
Cancer, 50 (1982), pp. 2.751-2.756
[46.]
A. Veronesi, V. Zagonel, M. Santarossa, et al.
Cisplatinum and. etoposide combination chemotherapy of advanced non-oat cell bronchogenic carcinoma.
Cancer Chemther Pharmacol, 11 (1983), pp. 35-37
[47.]
T.P. Miller, R.B. Vance, F.R. Ahmann, S.R. Rodney.
Extensive non-small cell lung cancer treated vith mitomycin, cisplatin and vindesine (MiPE). A Southwest Oncology Group Study.
Cancer Treat Rep, 70 (1986), pp. 1.101-1.104
[48.]
R.L. Woods, J.A. Levi, J. Page, et al.
Non small cell cancer: A randomized comparison of chemotherapy with no chemotherapy.
Proc ASCO, 4 (1985), pp. 177
[49.]
M.G. Kris, R.J. Gralla, M.S. Wertheim, et al.
Trial of the combination of mitocymin, vindesine and cisplatin in patients with advanced non-small cell lung cancer.
Cancer Treat Rep, 70 (1986), pp. 1.091-1.096
[50.]
N. Thatcher, D.B. Smith, M.J. Lind, et al.
Double alkylating agent therapy with ifosfamide and cyclophosphamide for advanced non-small cell lung cancer From the Manchester Lung Tumour Group.
Cancer, 61 (1988), pp. 14-18
[51.]
C.E. Araujo, M. De Marco, M. Sapositi.
Tratamiento del cáncer de pulmón de células no pequeñas con ifosfamida/mesna y cisplatino.
Oncología Iberoamericana, Excerpta Medica Ed Nauta, (1987), pp. 777-788
[52.]
H.G. Manke, P. Drings.
Quimioterapia de los carcinomas broncopulmonares de células no pequeñas con la combinación de ifosfamida y etoposido.
Oncología Iberoamericana, Excerpta Media Barcelona Ed. Nauta, (1987), pp. 789-799
[54.]
C. García Girón, A. Ordoñez, J.I. Jalón, M.G. Barón.
Combination chemotherapy with ifosfamide, mitomycin and cisplatin in advanced non-small cell lung cancer.
Cancer Treat Rep, 71 (1987), pp. 851-853
[55.]
M. González Barón, C. García Girón, J. Vicente, et al.
Phase I-II trial with ifosfamide, mitomycin and carboplatin in advanced non-small cell lung cancer.
Lung Cancer, 4 (1988), pp. 128
[56.]
R.S. Folman, M. Rosman.
The role of chemotherapy in non-small cell lung cancer The comunity perspective.
Sem Oncol, 15 (1988), pp. 16-21
[57.]
J.C. Ruckdeschel, D.M. Finkelstein, D.S. Ettinger, et al.
A randomized trial of the four most active regimens for metastatic non-small cell lung cancer.
J Clin Oncol, 4 (1986), pp. 14-22
[58.]
R.J. Simes.
Risk-benefit relationship in cancer clinical trials: the ECOG experience in non-small cell lung cancer.
J Clin Oncol, 3 (1985), pp. 462-472
[59.]
E.C. Holmes, M. Gail, Lung Cancer Study Group.
Surgical Adjuvant therapy for stage II and III adenocarcinoma and large cell undifferentiated carcinoma.
J Clin Oncol, 4 (1986), pp. 710-715
[60.]
E.C. Holmes.
Surgical adjuvant chemotherapy in non-small cell lung cancer.
Sem Oncol, 15 (1988), pp. 255-260
[61.]
J. Klastersky, R. Feld, J.P. Kleisbauer, P. Rocmans.
Treatment of N2 non-small cell lung cancer.
Lung Cancer, 4 (1988), pp. 61-63
[62.]
R.H. Jacobs, A. Awan, J.D. Bitran, et al.
Prophylactic cranial irradiation in adenocarcinoma of the lung: A possible role.
Cancer, 59 (1987), pp. 2.016-2.019
[63.]
B.R. Griffin, R.B. Livingston, G.R. Stewart, et al.
Prophylactic cranial irradiation for limited non-small cell lung cancer.
Cancer, 62 (1988), pp. 36-39
[64.]
R.A. Figlin, S. Plantadosi, R. Feld, The Lung Cancer Study Group.
Intracranial recurrence of carcinoma after complete surgical resection of stage I II and III non-small cell lung cancer.
N Eng J Med, 318 (1988), pp. 1.300-1.305
[65.]
A.L. Harris.
Drug resistence to cancer chemotherapy.
Drugs Today, 20 (1984), pp. 657-663
[66.]
W.K. Evans.
Adjuvant therapy for non-small cell lung cancer.
Lung Cancer, 4 (1988), pp. 64-69
[67.]
S.A. Rosenberg.
Inmunoterapia adoptiva del cáncer mediante células killer activadas con linfoquinas e interleuquina-2 recombinante.
Avances de Oncología 1986 V T De Vita, Espaxs SA, (1987), pp. 75-115
[68.]
P. Bononi, C. Mehta, J. Ruckdeschel.
Phase II-III trial in patients with metastasic non-small cell lung cancer An ECOG study.
Proc ASCO, 6 (1987), pp. 177
[69.]
R.F. Ozols, K. Cowan.
Nuevos aspectos de la resistencia clínica a fármacos.
Avances en Oncología 1986 VT De Vita, Espaxs S A, (1987), pp. 157-188
[70.]
Ch. Myers.
El fenómeno de resistencia farmacológica pleiotrópica.
Avances en Oncología 1986 VT De Vita, Espaxs S A, (1988), pp. 45-60
[71.]
A. Wozmick, A. Herskovic, Z. Steiger.
Treatment of locally advanced non-small cell lung cancer with infusional VP-16 and cisplatinum and concurrent radiation therapy.
Proc ASCO, 213 (1988), pp. 823
[72.]
N. Niederle, W. Alberti, M. Stuschke.
Prospective randomized study comparing immediate radiotherapy, chemo plus radiotherapy or delayed radiotherapy in limited disease non-small cell lung cancer.
Proc ASCO, 214 (1988), pp. 830
[73.]
R.O. Dillman, S.L. Seagren, K. Propert.
Protochemotherapy improves survival in regional non-small cell lung cancer.
Proc ASCO, 195 (1988), pp. 753
[74.]
R.C. Spain.
Neoadjuvant mitomycin C, cisplatin and infusion vinblastine in locally and regionally advanced non-small cell lung cancer: problems and progress from the perspective of long term follow-up.
Sem Oncol, (1988), pp. 6-15
[75.]
R.J. Gralla, M.G. Kris.
Chemotherapy in non-small cell lung cancer Results of recent trials.
Sem Oncol, 15 (1988), pp. 2-5
[76.]
A. Weitberg, A. Glicksman, J. Yashar.
Continous infusion cisplatinum, Concomitant radiotherapy and surgery for limited, inoperable non-small cell carcinoma of the lung.
Proc ASCO, 218 (1988), pp. 844
Copyright © 1989. Sociedad Española de Neumología y Cirugía Torácica
